Get the Stockscreener App
38.63
1.74%
0.66
Castle Biosciences Inc stock is traded at $38.63, with a volume of 377.26K.
It is up +1.74% in the last 24 hours and up +10.94% over the past month.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
See More
Previous Close:
$37.97
Open:
$38.93
24h Volume:
377.26K
Relative Volume:
0.95
Market Cap:
$1.13B
Revenue:
$219.79M
Net Income/Loss:
$-57.47M
P/E Ratio:
-17.97
EPS:
-2.15
Net Cash Flow:
$-19.25M
1W Performance:
-0.03%
1M Performance:
+10.94%
6M Performance:
+105.26%
1Y Performance:
+32.66%
1-Day Range:
$38.06
$39.19
1-Week Range:
$36.63
$39.19
52-Week Range:
$14.59
$40.61
Castle Biosciences Inc Stock (CSTL) Company Profile
Name
Castle Biosciences Inc
Sector
Industry
Phone
866-788-9007
Address
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
Compare CSTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
38.63 | 1.11B | 219.79M | -57.47M | -19.25M | -2.15 |
|
TMO
Thermo Fisher Scientific Inc
|
572.28 | 217.50B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
226.33 | 164.13B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
704.20 | 56.49B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
139.68 | 40.44B | 6.95B | 1.30B | 1.15B | 4.5714 |
|
IQV
Iqvia Holdings Inc
|
222.26 | 38.48B | 15.90B | 1.28B | 2.21B | 7.2842 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Apr-30-21 | Initiated | Lake Street | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-27-19 | Reiterated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | BTIG Research | Buy |
| Aug-19-19 | Initiated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | Robert W. Baird | Outperform |
| Aug-19-19 | Initiated | SVB Leerink | Outperform |
View All
Castle Biosciences Inc Stock (CSTL) Latest News
Castle Biosciences (NASDAQ:CSTL) Given New $50.00 Price Target at BTIG Research - MarketBeat
Castle Biosciences, Inc. $CSTL Shares Bought by Braidwell LP - MarketBeat
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Castle Biosciences (CSTL) Highlights Breakthrough in Barrett's E - GuruFocus
Castle Biosciences Announces Publication of Study Confirming TissueCypher® Test's Efficacy in Risk Stratification for Barrett's Esophagus Patients - Quiver Quantitative
BTIG Maintains Castle Biosciences (CSTL) Buy Recommendation - Nasdaq
Systematic Review and Meta-Analysis Confirms TissueCypher® - GlobeNewswire
Expert Melanoma Panel Recommends Castle Biosciences DecisionDx-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma - marketscreener.com
Castle Biosciences Announces Endorsement of DecisionDx-Melanoma Test in Independent Expert Consensus Paper - Quiver Quantitative
Expert Melanoma Panel Recommends Castle Biosciences’ - GlobeNewswire
Castle Biosciences (NASDAQ:CSTL) Insider Sells $53,600.17 in Stock - MarketBeat
Here's Why 'Trend' Investors Would Love Betting on Castle Biosciences (CSTL) - Yahoo Finance
New York State Common Retirement Fund Acquires 52,671 Shares of Castle Biosciences, Inc. $CSTL - MarketBeat
Castle Biosciences, Inc. $CSTL Shares Purchased by Schroder Investment Management Group - MarketBeat
Will Castle Biosciences Inc. stock attract more institutional investorsFed Meeting & Reliable Price Breakout Signals - Newser
XTX Topco Ltd Increases Stock Holdings in Castle Biosciences, Inc. $CSTL - MarketBeat
Geode Capital Management LLC Boosts Stake in Castle Biosciences, Inc. $CSTL - MarketBeat
8,362 Shares in Castle Biosciences, Inc. $CSTL Purchased by Elevation Point Wealth Partners LLC - MarketBeat
Castle Biosciences stock hits 52-week high at 40.61 USD By Investing.com - Investing.com Australia
Castle Biosciences stock hits 52-week high at 40.61 USD - Investing.com
Summit Global Investments Lowers Stake in Castle Biosciences, Inc. $CSTL - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Grows Stock Position in Castle Biosciences, Inc. $CSTL - MarketBeat
Derek Maetzold Sells 5,115 Shares of Castle Biosciences (NASDAQ:CSTL) Stock - MarketBeat
Is Castle Biosciences Inc. stock a buy before product launches2025 Analyst Calls & Fast Entry Momentum Trade Alerts - BỘ NỘI VỤ
Castle Biosciences (NASDAQ:CSTL) Hits New 52-Week HighTime to Buy? - MarketBeat
CSTL Form 4: CEO stock sale and updated insider holdings - Stock Titan
Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 4,693 Shares - MarketBeat
CEO Maetzold Files To Sell 10,712 Of Castle Biosciences Inc [CSTL] - TradingView
How Much Upside is Left in Castle Biosciences (CSTL)? Wall Street Analysts Think 50.08% - MSN
Castle Biosciences Executive Sells Shares - TradingView
Officer Juvenal Sells 4,693 ($167K) Of Castle Biosciences Inc [CSTL] - TradingView
[Form 4] CASTLE BIOSCIENCES INC Insider Trading Activity - Stock Titan
Top 5 Articles of the Week: November 16-21 - Dermatology Times
Is Pune Es Valuation Cheap Compared to Growth PeersChart Pattern Recognition & Superior Wealth Building - earlytimes.in
Castle Biosciences (CSTL) is on the Move, Here's Why the Trend Could be Sustainable - MSN
Castle Biosciences partners with SciBase for diagnostic tests - MSN
What Makes Castle Biosciences (CSTL) a New Strong Buy Stock - MSN
Castle Biosciences, Inc. (086.F) stock price, news, quote and history - Yahoo Finance UK
Castle Biosciences (NASDAQ:CSTL) Sets New 1-Year HighTime to Buy? - MarketBeat
Castle Biosciences stock hits 52-week high at $35.68 By Investing.com - Investing.com Canada
Castle Biosciences stock hits 52-week high at $35.68 - Investing.com
Can Castle Biosciences Inc. stock deliver consistent earnings growthJuly 2025 Institutional & Real-Time Chart Pattern Alerts - newser.com
Castle Biosciences earns Houston Top Workplace title for fifth year - Traders Union
Castle Biosciences (CSTL): Evaluating Valuation as New Melanoma Test Data Gains Attention at Major Oncology Congress - Yahoo Finance
Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth - MSN
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Castle Biosciences, Inc. (CSTL) Competitors - Meyka
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year - The Manila Times
Zacks.com featured highlights include Perimeter Solutions, Interface, Castle Biosciences and Great Lakes Dredge & Dock - sharewise.com
Castle Biosciences, Inc. $CSTL Shares Sold by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Will Castle Biosciences Inc. stock remain a Wall Street favorite2025 Volatility Report & Reliable Trade Execution Plans - newser.com
Castle Biosciences Inc Stock (CSTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.15%
0.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):